FDA Reverses Position On Fabre-Kramer's Gepirone, Clearing Way For Approval
This article was originally published in The Pink Sheet Daily
Executive Summary
Dispute resolution win means focus for antidepressant Travivo (gepirone extended-release) shifts to labeling, post-marketing and manufacturing despite going 2 for 12 in clinical trials.